Tissue Repair Ltd (TRP.AX)
AUD 0.24
(2.13%)
AUD 0.24
(2.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.35 Million AUD | 171.62% |
| 2023 | 497.34 Thousand AUD | -11.13% |
| 2022 | 559.64 Thousand AUD | 4.41% |
| 2021 | 536 Thousand AUD | 62.86% |
| 2020 | 329.11 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.35 Million AUD | 69.89% |
| 2024 Q2 | 795.16 Thousand AUD | 1.03% |
| 2024 FY | 1.35 Million AUD | 171.62% |
| 2024 Q1 | 787.06 Thousand AUD | 40.64% |
| 2024 Q4 | 1.35 Million AUD | 0.0% |
| 2023 Q1 | 625.48 Thousand AUD | 11.76% |
| 2023 FY | 497.34 Thousand AUD | -11.13% |
| 2023 Q3 | 490.79 Thousand AUD | -21.66% |
| 2023 Q4 | 559.64 Thousand AUD | 14.03% |
| 2023 Q2 | 626.46 Thousand AUD | 0.16% |
| 2022 Q1 | 535.67 Thousand AUD | -93.33% |
| 2022 FY | 559.64 Thousand AUD | 4.41% |
| 2022 Q4 | 559.64 Thousand AUD | 0.15% |
| 2022 Q3 | 558.78 Thousand AUD | 4.31% |
| 2022 Q2 | 535.67 Thousand AUD | 0.0% |
| 2021 Q3 | 8.03 Million AUD | 0.0% |
| 2021 FY | 536 Thousand AUD | 62.86% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | 8.03 Million AUD | 0.0% |
| 2020 FY | 329.11 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 61.866% |
| Biome Australia Limited | 5.37 Million AUD | 74.859% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 96.977% |
| Biotron Limited | 737.5 Thousand AUD | -83.171% |
| Acrux Limited | 5.68 Million AUD | 76.246% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 75.102% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 63.803% |
| BTC Health Limited | 203.94 Thousand AUD | -562.377% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 89.449% |
| CSL Limited | 27.88 Billion AUD | 99.995% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 83.786% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 95.195% |
| Immutep Limited | 10.97 Million AUD | 87.696% |
| Memphasys Limited | 5.59 Million AUD | 75.844% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 96.841% |
| Noxopharm Limited | 1.28 Million AUD | -4.834% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 41.911% |
| Race Oncology Limited | 1.91 Million AUD | 29.509% |
| Starpharma Holdings Limited | 8.69 Million AUD | 84.469% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 68.057% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -340.25% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -266.649% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 85.562% |
| Patrys Limited | 691.36 Thousand AUD | -95.397% |
| Orthocell Limited | 22.08 Million AUD | 93.883% |
| Imugene Limited | 33.14 Million AUD | 95.924% |
| PYC Therapeutics Limited | 10.18 Million AUD | 86.735% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 16.915% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -15.358% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 34.315% |
| Nanollose Limited | 465.64 Thousand AUD | -190.116% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -212.977% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -1476.63% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 60.578% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -29.196% |
| Nyrada Inc. | 855.63 Thousand AUD | -57.884% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.458% |
| Dimerix Limited | 13.89 Million AUD | 90.276% |
| PharmAust Limited | 896.6 Thousand AUD | -50.668% |
| Hexima Limited | 248.67 Thousand AUD | -443.252% |
| AnteoTech Limited | 4.07 Million AUD | 66.851% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 62.311% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 91.5% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -43.478% |
| Actinogen Medical Limited | 1.61 Million AUD | 16.372% |
| Immuron Limited | 2.84 Million AUD | 52.442% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 44.332% |